CONGRESS INFORMATION

ww

w.a

lpe-

adri

a-m

edic

ine.

com

Congress Center Wörthersee, Pörtschach, Austria Friday 16 May (4 pm) to Saturday 17 May (2 pm)

2 PreliMinAry reMArkSCOnGreSS AlPe ADriA rHeUMATOlOGy 2014

Dr. Peter Kaiser

Dr. Peter kaiserGovernor of Carinthia Patronage

Dr. Beate Prettner

Dear congress members,

Being a physician by myself, i understand the fast-moving pace of the medical sector and the resulting need for ongoing training and exchanging ideas – especially between state borders. And what better ‘host’ for ‘Alpe Adria rheumatology 2014’ than the health state of Carinthia with its excellent and exemplary health expertise, in particular compared with international standards.

i would like to thank those responsible at the Department of internal Medicine and rheumatology at the elisabethinen-krankenhaus klagenfurt for organising this very special event. i look forward to a successful conference and wish all the congress participants a warm welcome to Pörtschach by the beautiful lake Wörthersee.

Deputy Governor Dr. Beate Prettner Local Minister of Health for CarinthiaPatronage

2

3

ww

w.a

lpe-

adri

a-m

edic

ine.

com

PreliMinAry reMArkSCOnGreSS AlPe ADriA rHeUMATOlOGy 2014

Hans Jörg Neumann & Markus Gaugg

Dear colleague,

Our discipline has been playing a pioneering role in the application of modern immunomodulatory treatments for around 20 years. This welcome development involves an increasing need for ongoing medical training. Plans for a regional advanced training concept at an international level seem sensible in these times of increasing specialisation.

We have decided to focus on practice-relevant diagnostics and treatment of inflammatory rheumatic diseases within the context of modern research results.

Translation of these results in a clinic treatment setting is only possible in collaboration with the pharmaceuticals industry whose representatives we have to thank for their excellent collaboration.

This meeting should serve to establish medical cooperation within the Alpe-Adria region and to make new contacts across old borders. This is the success we as the organisers hope to achieve.

your attendance counts towards this success!

We look forward to welcoming you to Pörtschach am Wörthersee. Best wishes

Hans Jörg neumann Markus Gaugg Congress president Congress secretary

3

ww

w.a

lpe-

adri

a-m

edic

ine.

com

44

5

ww

w.a

lpe-

adri

a-m

edic

ine.

com

SCienTiFiC PrOGrAM COnGreSS AlPe ADriA rHeUMATOlOGy 2014

Friday, May 16th, 2014 15:30 Get together16:00 Opening Governor of Carinthia: Dr. Peter kaiser Deputy Governor of Carinthia, Representative of the Local Health

Authority: Dr. Beate Prettner President of the ÖGR (Austrian Society for Rheumatology and

Rehabilitation): Dr. Gabriele eberl Congress President: Dr. Hans Jörg neumann, MSc, Head Department internal

Medicine, General Hospital of the elisabethinen klagenfurt a. W. Congress Secretary: Dr. Markus Gaugg, Department of rheumatology, General

Hospital of the elisabethinen klagenfurt a. W.

16:15 1st Session: Systemic Autoimmune Disease Chair: Gabriele eberl (AT), iztok Holc (SlO) 16:15-16:35 1st Speech: Carlo Salvarani (iT): Systemic Vasculitis: news16:40-17:00 2nd Speech: Alojzija Hocevar (SlO): Systemic Vasculitis: Clinical Practice 17:05-17:25 3rd Speech: Georg Stummvoll (AT): immunoadsorption (iAS) in lupus nephritis 17:30-17:55 George Bertsias (Gr): lecture: State of the art in lupus nephritis18:00 end of 1st Session

Saturday, May 17th, 201409:00-12:20 Sonography Workshop: Christian Dejaco (AT)

09:00 2nd Session: Advances in Targeted Therapies: Update 2014 Chair: Burkhard F. leeb (AT) , Carlomaurizio Montecucco (iT) 09:05-09:25 1st Speech: Metka koren krajnc (SlO): Ankylosing Spondylitis 09:25-09:55 2nd Speech: Hans-Peter Brezinschek (AT): rheumatoid Arthritis 10:00-10:20 3rd Speech: leonardo Punzi (iT): Psoriatic Arthritis 10:20-10:50 Coffee Break

11:00 3rd Session: Biologic Therapies and Cancer Comorbidity: Does it matter? Chair: Winfried Graninger (AT), Artur Pahor (SlO)11:00-11:20 1st Speech: roberto Caporali (iT)11:25-11:45 2nd Speech: Hans Jörg neumann (AT)11:50-12:10 Wrap Up: AlPe ADriA rHeUMATOlOGy 2014 ludwig erlacher (AT)12:10-12:20 Discussion 12:20 Ending of the Symposium: Markus Gaugg (AT)12:25 Closing remarks: Hans Jörg neumann (AT)

66

7

ww

w.a

lpe-

adri

a-m

edic

ine.

com

CHAirS AnD SPeAkerSCOnGreSS AlPe ADriA rHeUMATOlOGy 2014

Bertsias George Prof. Dr., Department of rheumatology, University of Crete, Clinical immunology and Allergy, Medical School, Heraklion, Gr

Brezinschek Hans-Peter A. o. Prof. Dr., klinische Abteilung für rheumatologie und immunologie, Medizinische Universität, Graz, AT

Caporali Roberto Dr., Department of rheumatology, University and irCCS Policlinico S. Matteo, Pavia, iT

Dejaco Christian Ass. Prof. Doz. Dr., PhD, Medizinische Universität, Graz, AT

Eberl Gabriele Dr., MBA, klinikum Malcherhof Baden r-SkA Baden, Präsidentin der Österr. Gesellschaft für rheumatologie und rehabilitation ÖGr, Baden, AT

Erlacher Ludwig Prof. Dr., 2. Medizinische Abteilung mit rheumatologie und Osteologie sowie Akutgeriatrie, Sozialmedizinisches Zentrum Süd – kaiser-Franz-Josef-Spital, Wien, AT

Gaugg Markus Dr., A. ö. krankenhaus der elisabethinen, klagenfurt a. W., AT

Graninger Winfried Prof. Dr., klinische Abteilung für rheumatologie & immunologie, Medizinischen Universität, Graz, AT

Hocevar Alojzija Mag. Dr., Department of rheumatology, University Medical Centre, ljubljana, SlO

Holc Iztok Ass. Prof. MD, PhD, President of the Slovenian Society of rheumatology, Department of rheumatology, University Medical Centre, Maribor, SlO

Krajnc Metka Koren Mag., UkC – Univerzitetni klinici Center, Maribor, SlO

Leeb Burkhard F. Doz. Dr., 2. Medizinische Abteilung, landesklinikum korneuburg-Stockerau, AT

Montecucco Carlomaurizio Prof. MD, Unità Operativa di reumatologia, irCCS Policlinico S. Matteo, Pavia, iT

Neumann Hans Jörg Dr., MSc, Abteilung für innere Medizin, A. ö. krankenhaus der elisabethinen, klagenfurt a. W., AT

Pahor Artur Prof. Dr., interno Medici, UkC – Univerzitetni klinici Center, Maribor, SlO

Punzi Leonardo Prof. Dr., Department of Medicine DiMeD, rheumatology Unit University of Padova, Padova, iT

Salvarani Carlo Dr., Department of rheumatology, Arcispedale S. Maria nuova – irCCS, reggio emilia, iT

Stummvoll Georg Doz. Dr., Universitätsklinik für innere Medizin iii, Medizinische Universität, Wien, AT

8 SPOnSOrinGCOnGreSS AlPe ADriA rHeUMATOlOGy 2014

We would like to thank our sponsors for kindly supporting Alpe Adria rheumatology 2014.

Platinum

Silver

Others

UniQA GeneralAgentur Markus Perkonigg kG, Wienergasse 11, 9020 klagenfurt

9

ww

w.a

lpe-

adri

a-m

edic

ine.

com

PrODUCT CHArACTeriSTiCS

Enbrel

enbrel 25 mg powder and solvent for solution for injection, enbrel 25 mg solution for injection in pre-filled syringe, enbrel 50 mg solution for injection in pre-filled syringe, enbrel 50 mg solution for injection in pre-filled pen, enbrel 10 mg powder and solvent for solution for injection for paediatric use

Qualitative and quantitative composition: each vial contains 10/25 mg of etanercept, each pre-filled syringe contains 25 mg/50 mg of etanercept, each pre-filled pen contains 50 mg etanercept. list of excipients: enbrel 25 mg powder and solvent for solution for injection & enbrel 10 mg powder and solvent for solution for injection for paediatric use: Powder: Mannitol (e421), sucrose and trometamol.

Solvent: Water for injection. enbrel 25 mg solution for injection in pre-filled syringe, enbrel 50 mg solution for injection in pre-filled syringe, enbrel 50 mg solution for injection in pre-filled pen: Sucrose, sodium chloride, l-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium phosphate dibasic dihydrate, water for injection.

Therapeutic indications: enbrel 25 mg powder and solvent for solution for injection, enbrel 25 mg solution for injection in pre-filled syringe, enbrel 50 mg solution for injection in pre-filled syringe, enbrel 50 mg solution for injection in pre-filled pen: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, paediatric plaque psoriasis. enbrel 10 mg powder and solvent for solution for injection for paediatric use: juvenile idiopathic arthritis, paediatric plaque psoriasis. (For details please refer to the Summary of Product Characteristics)

Contraindications: Hypersensitivity to the active substance or to any of the excipients. Sepsis or risk of sepsis. Treatment with enbrel should not be initiated in patients with active infections, including chronic or localised infections. Pharmacotherapeutic group: immunosuppressants, Tumour necrosis Factor alpha (TnF-a) inhibitors, ATC code: l04AB01. Marketing authorisation holder: Pfizer limited, ramsgate road, Sandwich, kent CT13 9nJ, United kingdom. Date of revision of the text: 05/2013. General classification for supply: Subject to medical prescription, available in pharmacies only, non-renewable prescription. For details of special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, pregnancy and lactation and undesirable effects please refer to the published Summary of Product Characteristics.

Simponi

Name of the medicinal product: Simponi 50 mg solution for injection in pre-filled pen. Simponi 50 mg solution for injection in pre-filled syringe. Qualitative and Quantitative Composition: One 0.5 ml pre-filled pen contains 50 mg of golimumab*. One 0.5 ml pre-filled syringe contains 50 mg of golimumab*. * Human igG1k monoclonal antibody produced by a murine hybridoma cell line with recombinant DnA technology. each pre-filled pen contains 20.5 mg sorbitol per 50 mg dose. each pre-filled syringe contains 20.5 mg sorbitol per 50 mg dose. List of other excipients: Sorbitol (e 420) l-histidine l-histidine monohydrochloride monohydrat Polysorbate 80 Water for injections. Therapeutic indications: rheumatoid arthritis (rA)Simponi, in combination with methotrexate (MTX), is indicated for: • the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying

anti-rheumatic drug (DMArD) therapy including MTX has been inadequate. • the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX. Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMArD) therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Ankylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded

10inadequately to conventional therapy. Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active tuberculosis (TB) or other severe infections such as sepsis, and opportunistic infections. Moderate or severe heart failure (nyHA class iii/iV). Fertility, pregnancy and lactation: Women of childbearing potential Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last golimumab treatment. Pregnancy There are no adequate data on the use of golimumab in pregnant women. Due to its inhibition of TnF, golimumab administered during pregnancy could affect normal immune responses in the newborn. Studies in animals do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. The use of golimumab in pregnant women is not recommended; golimumab should be given to a pregnant woman only if clearly needed. Golimumab crosses the placenta. Following treatment with a TnF-blocking monoclonal antibody during pregnancy, the antibody has been detected for up to 6 months in the serum of the infant born by the treated woman. Consequently, these infants may be at increased risk of infection. Administration of live vaccines to infants exposed to golimumab in utero is not recommended for 6 months following the mother’s last golimumab injection during pregnancy. Breast-feeding it is not known whether golimumab is excreted in human milk or absorbed systemically after ingestion. Golimumab was shown to pass over to breast milk in monkeys, and because human immunoglobulins are excreted in milk, women must not breast feed during and for at least 6 months after golimumab treatment. Fertility no animal fertility studies have been conducted with golimumab. A fertility study in mice, using an analogous antibody that selectively inhibits the functional activity of mouse TnFa, showed no relevant effects on fertility. Pharmacotherapeutic group: Tumour necrosis factor alpha (TnF-a) inhibitors, ATC code: l04AB06 Marketing Authorisation Holder: Janssen Biologics B.V. einsteinweg 101 2333 CB leiden niederlande Dispensing: nr, available only on prescription and only in pharmacies. Information as of: June 2013 For further Information on Posology and method of administration, Special warnings and precautions for use, Interaction with other medicinal products and other forms of interaction, Effects on ability to drive and use machines, Undesirable effects, Overdose, Pharmacodynamic properties and Pharmacokinetic properties refer to the published summary of product characteristics.

Remicade

Name of the Medicinal Product remicade 100 mg powder for concentrate for solution for infusion.

Qualitative and Quantitative Composition each vial contains 100 mg of infliximab. infliximab is a chimeric human-murine igG1 monoclonal antibody produced in murine hybridoma cells by recombinant DnA technology. After reconstitution each ml contains 10 mg of infliximab.

List of other excipients: Sucrose, Polysorbate 80, Monobasic sodium phosphate, Dibasic sodium phosphate

Therapeutic indications rheumatoid arthritis remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: • adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including

methotrexate, has been inadequate. • adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMArDs. in these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated.

Adult Crohn’s disease remicade is indicated for: • treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and

adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

• treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

11

ww

w.a

lpe-

adri

a-m

edic

ine.

com

Paediatric Crohn’s disease remicade is indicated for treatment of severe, active Crohn’s disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy.

Ulcerative colitis remicade is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Paediatric ulcerative colitis remicade is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

Ankylosing spondylitis remicade is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

Psoriatic arthritis remicade is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMArD therapy has been inadequate. remicade should be administered - in combination with methotrexate - or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated remicade has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

Psoriasis remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

Contraindications Patients with a history of hypersensitivity to infliximab, to other murine proteins, or to any of the excipients listed in section 6.1. Patients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections. Patients with moderate or severe heart failure (nyHA class iii/iV).

Fertility, pregnancy and lactation Women of childbearing potential Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last remicade treatment.

Pregnancy The moderate number (approximately 450) of prospectively collected pregnancies exposed to infliximab with known outcomes, including a limited number (approximately 230) exposed during the first trimester, does not indicate unexpected effects on pregnancy outcome. Due to its inhibition of TnFa, infliximab administered during pregnancy could affect normal immune responses in the newborn. in a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TnFa, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. The available clinical experience is too limited to exclude a risk, and administration of infliximab is therefore not recommended during pregnancy. infliximab crosses the placenta and has been detected up to 6 months in the serum of infants born to women treated with infliximab during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of live vaccines to infants exposed to infliximab in utero is not recommended for 6 months following the mother’s last infliximab infusion during pregnancy. Breast-feedingit is unknown whether infliximab is excreted in human milk or absorbed systemically after ingestion. Because human immunoglobulins are excreted in milk, women must not breast feed for at least 6 months after remicade treatment.

FertilityThere are insufficient preclinical data to draw conclusions on the effects of infliximab on fertility and general reproductive function.

Pharmacotherapeutic properties: tumour necrosis factor alpha (TnFa) inhibitors, ATC code: l04AB02.

Marketing Authorisation Holder: Janssen Biologics B.V., einsteinweg 101, 2333 CB leiden, niederlande

Dispensing: available only on prescription and only in pharmacies.

Information as of: June 2013 For further Information on Posology and method of administration, Special warnings and precautions for use, Interaction with other medicinal products and other forms of interaction, Effects on ability to drive and use machines, Undesirable effects, Overdose, Pharmacodynamic properties and Pharmacokinetic properties refer to the published summary of product characteristics.

imprint: Verein Alpe Adria rheumatology Austria e.V., kölnhofallee 5, 9300 St. Veit an der Glan, Austria, Tel.: +43 463 5830-261; responsible for the contents: Dr. Hans Jörg neumann, MSc, Dr. Markus Gaugg, Photos: Gernot Gleiss, Helge Bauer, Graphic: www.bossgrafik.at

www.alpe-adria-medicine.comAK Biologikatherapie

COnGreSS OrGAniSATiOn Verein Alpe Adria rheumatology Austria e.V. kölnhofallee 5, 9300 St. Veit/Glan, Austria